Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is a well-diversified and sustainable company with potential upside from recent acquisitions and partnerships, a focus on sustainability, and a strong human capital management structure. The company has a high-margin operating model, diverse portfolio of royalty-generating assets, and a strategic focus on acquiring royalties for drugs that address unmet medical needs, making it a strong investment opportunity with a target valuation of $252 per share. However, they also face risks such as competition and slow sales, with a downside scenario for their valuation at $98 per share. Overall, Ligand's strong management, diverse portfolio, and potential for future growth make it a positive investment outlook.

Bears say

Ligand Pharmaceuticals is facing challenges with its business model and partnerships. The company's financials are heavily dependent on royalties from commercialized products and license and milestone payments, making it vulnerable to setbacks in its partnerships. The recent approval of FILSPARI for FSGS and potential future revenue may provide a short-term boost, but the company's long-term sustainability is questionable. Additionally, the lack of diversity in the company's board and senior management team raises concerns about its ability to adapt to changing market trends.

Ligand Pharmaceuticals (LGND) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of May 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $257.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $257.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.